Table 2.
Classifications based on CTCAE version 5.0 for haemoglobin, leukocytes, platelets, and creatinine were compared in percentages between patients undergoing 4-week and 6-week treatment intervals, both at baseline and the final treatment cycle. From baseline, in the 4-week treatment interval group, there were two instances of grade III anemia and one of grade III leukopenia. In the 6-week treatment interval group, one grade III anemia and one grade III thrombocytopenia were observed; however, the same patient already had grade III anemia at baseline. There were no other grade III/IV toxicities in either group
| 4-week treatment interval | 6-week treatment interval | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Grade 0 | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 0 | Grade 1 | Grade 2 | Grade 3 | Grade 4 | ||
| Creatinine | Baseline | 23/23 (100%) | 0 | 0 | 0 | 0 | 19/23 (82.6%) | 2/23 (8.7%) | 2/23 (8.7%) | 0 | 0 |
| Last cycle | 21/23 (91.3) | 2/23 (8.7%) | 0 | 0 | 0 | 21/23 (91.3%) | 2/23 (8.7%) | 0 | 0 | 0 | |
| Haemoglobin | Baseline | 2/23 (8.7%) | 18/23 (78.3) | 3/23 (13.0) | 0 | 0 | 3/23 (13.0%) | 16/23 (69.6%) | 3/23 (13.0%) | 1/23 (4.3%) | 0 |
| Last cycle | 0 | 12/23 (52.2%) | 9/23 (39.1%) | 2/23 (8.7%) | 0 | 0 | 15/23 (65.2%) | 7/23 (30.4%) | 1/23 (4.3%) | 0 | |
| Platelets | Baseline | 22/23 (95.7%) | 1/23 (4.3%) | 0 | 0 | 0 | 21/23 (91.3%) | 0 | 2/23 (8.7%) | 0 | 0 |
| Last cycle | 18/23 (78.3%) | 2/23 (8.7%) | 3/23 (13.0%) | 0 | 0 | 19/23 (82.6%) | 1/23 (4.3%) | 2/23 (8.7%) | 1/23 (4.3%) | 0 | |
| Leucocytes | Baseline | 20/23 (87.0%) | 1/23 (4.3%) | 2/23 (8.7%) | 0 | 0 | 21/23 (91.3%) | 2/23 (8.7%) | 0 | 0 | 0 |
| Last cycle | 11/23 (47.8%) | 9/23 (39.1%) | 2/23 (8.7%) | 1/23 (4.3%) | 0 | 19/23 (82.6%) | 3/23 (13.0%) | 1/23 (4.3%) | 0 | 0 | |